10-Q: Mirion Technologies Reports Strong Q3 2026 Growth

Mirion Technologies announced a significant increase in revenues for the third quarter of 2026, driven by strong performance in its Nuclear & Safety segment and strategic acquisitions.

Summary

• Mirion Technologies reported revenues of $277.8 million for the three months ended September 30, 2026, a 24.5% increase from $223.1 million in the same period of 2025.
• For the nine months ended September 30, 2026, revenues were $802.2 million, up 23.8% from $648.0 million in the prior year period.
• Net income for the third quarter of 2026 was $7.8 million, compared to $3.1 million in the third quarter of 2025.
• Net income for the nine months ended September 30, 2026 was $12.5 million, compared to $12.0 million in the same period of 2025.
• The Nuclear & Safety segment saw revenues increase to $194.0 million in Q3 2026 from $144.6 million in Q3 2025.
• The Medical segment's revenues grew to $83.8 million in Q3 2026 from $78.5 million in Q3 2025.
• Backlog stood at $1,248.2 million as of September 30, 2026, up from $1,104.3 million at December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, with strong revenue growth driven by acquisitions and organic performance, though offset by increased operating expenses and a shift in foreign currency impact.

Positives

• Total revenues increased by 24.5% to $277.8 million for the three months ended September 30, 2026, compared to the prior year period.
• Nine-month revenues grew by 23.8% to $802.2 million.
• Net income for Q3 2026 was $7.8 million, a significant improvement from $3.1 million in Q3 2025.
• The Nuclear & Safety segment showed strong revenue growth, increasing by $49.4 million year-over-year for the quarter.
• The Medical segment also contributed positively with revenue growth of $5.3 million year-over-year for the quarter.
• Gross profit increased by $27.0 million to $131.5 million for the three months ended September 30, 2026.
• Backlog increased to $1,248.2 million, indicating strong future revenue potential.

Negatives

• Selling, general, and administrative (SG&A) expenses increased by $17.0 million to $104.0 million for the three months ended September 30, 2026.
• Cost of revenues increased by $27.7 million to $146.3 million for the three months ended September 30, 2026.
• Income tax expense increased to $3.1 million for the three months ended September 30, 2026, from a benefit of $1.9 million in the prior year period.
• A shift from a foreign currency gain in the prior year to a foreign currency loss in the current period impacted results.
• Amortization expense increased due to recent acquisitions.

Risks

• Geopolitical and trade conditions, including those related to Russia, China, and the Middle East conflict, could impact global trade, supply chains, and financial markets.
• Government spending budgets and potential reductions or delays could affect revenues from government customers.
• Supply chain disruptions and difficulties with third-party manufacturers pose a risk to operations.
• Risks associated with government contracts, particularly long-term fixed-price contracts, including potential losses from underestimating costs.
• The public's perception of nuclear radiation and nuclear technologies could impact the business.
• Information technology disruptions, security issues, and cyberattacks are potential threats.
• The use of artificial intelligence and machine learning technologies carries risks of legal liability, regulatory action, and competitive harm.
• Fluctuations in foreign currency exchange rates, interest rates, tariffs, and inflation could impact debt service costs and overall financial performance.

Future Outlook

The company anticipates continued growth driven by its two segments, Nuclear & Safety and Medical, supported by ongoing trends in nuclear energy, healthcare, and defense. Management believes that net cash provided by operating activities, along with existing debt arrangements, will provide adequate liquidity for the next 12 months, supporting investments for growth and capital structure management. However, future access to capital markets is subject to various factors including credit rating, economic conditions, and market liquidity.

Management Comments

• Mirion management believes the Certrec business will be pivotal in expanding our offerings in the nuclear power market and further strengthen the development of Mirion's digital ecosystem.
• Mirion management believes that Paragon will provide Mirion's nuclear power customers with a more comprehensive suite of product offerings and services to meet their growing needs.
• Mirion management believes that Paragon will provide Mirion's nuclear power customers with a more comprehensive suite of product offerings and services to meet their growing needs. Additionally, the addition of Paragon significantly enhances Mirion's presence in the U.S. nuclear power market and the developing SMR commercial entrants.

Industry Context

StockSavvy.ai notes that Mirion's performance aligns with broader trends in the nuclear energy sector, which is seeing renewed interest due to clean energy initiatives and data center power demands. The Medical segment's growth also reflects the increasing demand for advanced healthcare technologies and quality assurance solutions.

Comparison to Industry Standards

• The company's revenue growth of 24.5% in Q3 2026 outpaces the general industrial manufacturing sector's growth, which has been more moderate.
• The Nuclear & Safety segment's revenue growth is particularly strong, benefiting from increased government and industry acceptance of nuclear energy as a clean source.
• The Medical segment's performance in Radiation Therapy Quality Assurance (RT QA) aligns with industry trends of increasing adoption of advanced software and hardware for improved patient outcomes and operational efficiencies.
• The company's backlog of $1.25 billion suggests a robust pipeline, which is a positive indicator compared to peers facing more uncertain demand.

Legal Proceedings

• The company is subject to various legal proceedings, claims, litigation, investigations, and contingencies arising out of the ordinary course of business. The resolution of these matters is not expected to have a material effect on results of operations, financial condition, or cash flows.

Stakeholder Impact

• Shareholders: Increased revenues and net income, along with a growing backlog, are positive indicators for shareholder value. Share repurchases also indicate a commitment to returning value.
• Employees: Increased compensation costs, including stock compensation, suggest investment in personnel, but also contribute to higher operating expenses.
• Creditors: The company remains in compliance with its debt covenants, indicating stability for creditors.
• Customers: The company's expanded product offerings through acquisitions (Certrec and Paragon) are expected to provide more comprehensive solutions to nuclear power customers.

Next Steps

• Continue to monitor macroeconomic conditions for future changes in assumptions or deterioration in market conditions, including impacts from rising long-term interest rates and geopolitical risks impacting global trade conditions, which could result in an impairment in one or more of the Company's reporting units.
• Perform the annual goodwill impairment assessment for all reporting units during the fourth quarter of 2026.
• Continue to monitor the social, political, regulatory, and economic environment in Russia and China and consider actions as appropriate.
• The Company expects $1.9 million in additional charges from restructuring actions in the next 12 months.

Key Dates

Recommendation

Mirion Technologies demonstrates strong revenue growth driven by strategic acquisitions and organic performance, alongside improved profitability. However, the increase in operating expenses, the shift in foreign currency impact, and the ongoing integration of acquisitions warrant a cautious approach. While the outlook is positive, the company's reliance on complex markets and potential geopolitical risks suggest a 'hold' recommendation until further clarity on sustained profitability and cost management emerges.

Keywords

Radiation Detection, Nuclear Safety, Medical Devices, Dosimetry, Radiation Therapy, Nuclear Power, Quality Assurance, Acquisitions